Organization | Roivant Sciences, Inc.

Roivant Sciences, Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 4

Founded: Basel Switzerland (2014)

Status: Acquired by Sumitomo (2023) → now Sumitomo Dainippon (2005)

Organization Overview

First Clinical Trial

2015

NCT02611921

First Marketed Drug

2017

desmopressin (ddavp)

First NDA Approval

2022

tapinarof (Vtama)

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (2)

desmopressin (ddavp) (2017)

tapinarof (Vtama) (2022 NDA)

Drugs in Phase 4 Trials (1)

tapinarof (Vtama) (11 trials)

Drugs in Phase 2 Trials (7)

Key: Roivant Sciences, Inc. (4) Acquired (3)

cerdulatinib (1 trial)

cromoglicic acid (Intal) (2 trials)

e6005 (1 trial)

gimsilumab (2 trials)

namilumab (2 trials)

rvt-3101 (1 trial)

rvt-501 (2 trials)

Drugs in Phase 1 Trials (7)

Key: Roivant Sciences, Inc. (4) Acquired (3)

ketamine (ketalar) (1 trial)

ksp-1007 (1 trial)

meropenem (merrem) (1 trial)

pembrolizumab (keytruda) (1 trial)

rodatristat ethyl (1 trial)

snx281 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Autism Spectrum Disorder (Phase 1)

Autistic Disorder (Phase 1)

Child Development Disorders, Pervasive (Phase 1)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Disease (Phase 1)

Eczema (Phase 2)

Psoriasis (Phase 3)

Vitiligo (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 26
# of Trial APIs: 15